VVAG Special
Venture capitalBoston · 5 people tracked
Find your way into VVAG Special
Fund manager profile
VVAG Special is a venture fund manager based in Boston. SEC filings show 1 venture fund on record, most recently VVAG Special Fund LLC ($40M offering) filed June 2018.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 5 people
from public directoriesWhat they invest in
from 1 of 1 portfolio companiesBiotech ×1Healthtech ×1Medical Devices ×1
HQs:United States×1
Investments · 1 tracked
founders shown can be your intro path
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)
BoardOWEN WITTE(Director)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPGVida VenturesGilead Sciences
Exits · 1
IPOs and acquisitions across the tracked portfolioAllogene TherapeuticsNASDAQ: ALLO
Portfolio news
latest coverage across their companiesAllogene Therapeutics · investing.com · Jul 15, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Allogene Therapeutics | 6.5% | $18.00 | Oct 2018 | $134.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is VVAG Special located?
- VVAG Special is headquartered in Boston, US.